In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on ESSA Pharma Inc (NASDAQ: EPIX), with a price target of $14. The company’s shares opened today at $4.01, close to its 52-week low of $2.
According to TipRanks.com, Pantginis has 0 stars on 0-5 star ranking scale with an average return of -11.3% and a 38.1% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
ESSA Pharma Inc has an analyst consensus of Moderate Buy, with a price target consensus of $0.70.
See today’s analyst top recommended stocks >>
The company has a one-year high of $51 and a one-year low of $2. Currently, ESSA Pharma Inc has an average volume of 108.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ESSA Pharma, Inc. is a pharmaceutical company. It engages in the development of small molecule drugs for the treatment of prostate cancer. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.
